Climatic change plays an integral part in planetary health and is amongst the most important global environmental aspect that has an impact on human health. The linkage between the environmental change and disease dynamics has been highlighted in recent times and hence, emphasis on environmental sustainability to reduce future epidemics. Present book focusses on the relationship between climatic change and epidemiological factors with an approach to reduce the global hotspots. The climatic changes relevant to periods of activity and variations in geographical distribution is addressed including interconnection of sustainability, population growth and environmental change. Features: Covers environmental management and waste to resource for future. Includes guidelines for analysis, assessment, and interventions for waste management. Discusses environmental impediments in the way of healthcare inclusions. Impresses upon the importance of clinical epidemiology to detect, treat, control, and prevent the spread of non-communicable diseases globally. Provides insights for the future health hazards that can be administered at the insignificant stage. This book aims at Graduate Students, Researchers, Professionals and Health Care Professionals in environmental engineering, waste management, climate change, and healthcare.

This ambitious reference surveys worldwide efforts at controlling the spread of tuberculosis, with special emphasis on the developing world. Case studies from China, Pakistan, Nigeria, Indonesia, and other frontline countries demonstrate a wealth of information on clinical, cultural, socioeconomic, and other relevant factors. This compilation provides a valuable resource for creating successful intervention and prevention strategies. State-of-the-science snapshots pinpoint where short- and long-term initiatives stand today, from early detection and vaccination programs to new genetic technologies and drug therapies. This diverse group of perspectives and approaches offers innovative paths toward control and realistic odds for containing the threat, especially in the face of current co-epidemics and new drug-resistant strains. Among the topics in the Handbook: Diagnosis of tuberculosis: current pipeline, unmet needs, and new developments Concurrence of tuberculosis and other major diseases The tuberculosis outbreak response, investigation, and control The promise of new TB vaccines DNA fingerprinting of Mycobacterium tuberculosis: a rich source of fundamental and daily applicable knowledge Global tuberculosis surveillance The Handbook of Global Tuberculosis Control is urgent reading for leadership and staff of non-governmental organizations, government agencies, academic institutions, research centers, hospitals, and potentially businesses with interests in tuberculosis control. Additionally, the book's focus on TB in developing countries will attract a wider audience of practitioners, particularly those working in the broader fields of global public health, epidemiology, international development, and the socioeconomics of infectious diseases.

Bayesian Analysis of Infectious Diseases -COVID-19 and Beyond shows how the Bayesian approach can be used to analyze the evolutionary behavior of infectious diseases, including the coronavirus pandemic. The book describes the foundation of Bayesian statistics while explicating the biology and evolutionary behavior of infectious diseases, including viral and bacterial manifestations of the contagion. The book discusses the application of Markov Chains to contagious diseases, previews data analysis models, the epidemic threshold theorem, and basic properties of the infection process. Also described are the chain binomial model for the evolution of epidemics. Features: Represents the first book on infectious disease from a Bayesian perspective. Employs WinBUGS and R to generate observations that follow the course of contagious maladies. Includes discussion of the coronavirus pandemic as well as many examples from the past, including the flu epidemic of 1918-1919. Compares standard non-Bayesian and Bayesian inferences. Offers the R and WinBUGS code on at www.routledge.com/9780367633868

This book examines the toxicological and health implications of environmental epigenetics and provides knowledge through an interdisciplinary approach. Included in this volume are chapters outlining various environmental risk factors such as phthalates and dietary components, life states such as pregnancy and ageing, hormonal and metabolic considerations and specific disease risks such as cancer cardiovascular diseases and other non-communicable diseases. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses.

*A focus on normal theory linking average power, expected power, predictive power, assurance, conditional Bayesian power and Bayesian power. *Extensions of the concepts to binomial, and time-to-event outcomes and non-inferiority trials *An investigation into the upper bound on average power, assurance and Bayesian power based on the prior probability of a positive treatment effect *Application of assurance to a series of trials in a development program and an introduction of the assurance of an individual trial conditional on the positive outcome of an earlier trial in the program, or to the successful outcome of an interim analysis *Prior distribution of power and sample size *Extension of the basic approach to proof-of-concept trials with dual success criteria *Investigation of the connection between conditional and predictive power at an interim analysis and power and assurance *Introduction of the idea of surety in sample sizing of clinical trials based on the width of the confidence intervals for the treatment effect, and an unconditional version.

Social psychiatry is a multidisciplinary field analyzing mechanisms of mental health issues comprehensively to contribute to society using the findings. Those findings include biological, psychological, and social aspects and they are based on psychiatry and connected with a wide variety of academic fields, including psychology, sociology, law, economics, and religious studies. Epidemiological research in psychiatry is a field of study in patients with psychiatric disorder attempting to investigate causes, to develop clinical applications of the results, and to determine applications to health services plans for individuals and/or communities. They are both foundation for understanding biopsychosocial view in psychiatry but not many comprehensive volumes covering the topic were not available until now. This book is thus a unique, comprehensive reference with evidence-based approach to provide concise summary of researches for such as schizophrenia, affective disorders, psychiatric disorders in the general practice setting, and disaster psychiatry, especially for the case of atomic bomb diseases. The studies were mostly carried out in the region of Nagasaki, the prefecture experienced a nuclear attack at the time of World War . Psychiatric findings in mental health problems among atomic bomb survivors and sufferers in Nagasaki has been established and Nagasaki is the only area that fulfills the conditions of the subject of the study of psychiatric epidemiology and social psychiatry which is going to be described in this book. This book provides a valuable resource not only for physicians and researchers in the field of psychiatry and mental health but for people who work for mental health welfare department."

Biostatistics for Practitioners: An Interpretative Guide for Medicine and Biology deals with several aspects of statistics that are indispensable for researchers and students across the biomedical sciences. The book features a step-by-step approach, focusing on standard statistical tests, as well as discussions of the most common errors. The book is based on the author's 40+ years of teaching statistics to medical fellows and biomedical researchers across a wide range of fields.

The Plague Years collects scholarly and essayistic reflections on literary, visual, and sonic representations of the COVID-19 and other pandemics. These are placed alongside poetry and short fiction written in the first two years of quarantine or isolation. This range expresses the intellectual and imaginative struggle and ingenuity entailed in coming to terms with the rampant spread of disease and its emotional, cultural, and political consequences. The contributions are from diverse contexts: Africa (from Egypt to South Africa), China, Japan, the US, and Scandinavia. They consider some of the array of contemporary engagements: poems translated from Mandarin about the traumas of the frontline, Chinese calligraphic poetry printed on cartons of PPE, comments on the literary history of representing epidemics and pandemics, political analyses of the post-truth present, and the role of life-writing and gaming in an interrupted world. Given the generative and creative obliquity of many of its parts, this collection shifts how one thinks about the diseased present and the archival pasts on which it draws. The chapters in this book were originally published as a special issue of English Studies in Africa.

On May 4, 1993, Cuba asked the international health community and the World Health Organization (WHO) to find the cause of a mysterious epidemic of blindness that was spreading uncontrollably. Contradictory hypotheses confronted the team of scientists on this mission. Is the epidemic the result of a plot to topple Castro, as the Cubans believe? Or exposure to radioactivity or an unidentified nerve toxin accidentally released by the Russian Army withdrawing from Cuba? Cuban Blindness: Diary of a Mysterious Epidemic Neuropathy is a firsthand account of the epidemic of blindness and the hardships of life in Cuba at the time of the "special period" that followed the collapse of the Soviet Union and the tightening of the US embargo. Dr. Roman-who was at the time Chief of Neuroepidemiology at the US National Institutes of Health-was a participant in this scientific mission and describes the neurological symptoms experienced by the victims of this epidemic disease, and narrates the epidemiologists' detective work struggling to solve the mystery. This book combines neuroscience and scientific discovery with political intrigue, finally bringing the reader to the unexpected solution provided by a WWII survivor of Changi POW Camp in Singapore. Cuban Blindness: Diary of a Mysterious Epidemic Neuropathy is a description of the neuroepidemiological study undertaken to identify the cause of the epidemic neurological disease that affected Cuba in 1993-1994.

*Includes new chapters on Fellowship Grants and Career Development Awards designed for graduate students, postdoctoral fellows, and early-career faculty *Provides strategies to highlight the "overall impact" of the grant, one of the most important aspects determining NIH funding in a new chapter on Significance and Innovation *Provides step-by-step guidelines for grant structure and style alongside broader strategies for developing a research funding portfolio *Explains how to avoid common errors and pitfalls, supplying critical dos and don'ts that aid in writing solid grant proposals *Illustrates key concepts with extensive examples from successfully funded proposals

Advanced Statistics in Regulatory Critical Clinical Initiatives is focused on the critical clinical initiatives introduced by the 21st Century Cure Act passed by the United States Congress in December 2016. The book covers everything from the outline of the initiatives to analysis on the effect on biopharmaceutical research and development. Advanced Statistics in Regulatory Critical Clinical Initiatives provides innovative ways to resolve common challenges in statistical research of rare diseases such small sample sizes and provides guidance for combined use of data. With analysis from regulatory and scientific perspectives this book is an ideal companion for researchers in biostatistics, pharmaceutical development, and policy makers in related fields. Key Features: Provides better understanding of innovative design and analysis of each critical clinical initiatives which may be used in regulatory review/approval of drug development. Makes recommendations to evaluate submissions accurately and reliably. Proposes innovative study designs and statistical methods for oncology and/or rare disease drug development. Provides insight regarding current regulatory guidance on drug development such as gene therapy and rare diseases.

Comparing and Contrasting the Impact of the COVID-19 Pandemic in the European Union challenges the use of uncontextualised comparisons of COVID-19 cases and deaths in member states during the period when Europe was the epicentre of the pandemic. This timely study looks behind the headlines and the statistics to demonstrate the value for knowledge exchange and policy learning of comparisons that are founded on an in-depth understanding of key socio-demographic and public health indicators within their policy settings. The book adopts innovative, integrated, multi-disciplinary international perspectives to track and assess a fast-moving topical subject in an accessible format. It offers a template for analysing policy responses to the COVID-19 pandemic and for using evidence-based comparisons to inform and support policy development.

With the critical role of statistics in the design, conduct, analysis and reporting of clinical trials or observational studies intended for regulatory purposes, numerous guidelines have been issued by regulatory authorities around the world focusing on statistical issues related to drug development. However, the available literature on this important topic is sporadic, and often not readily accessible to drug developers or regulatory personnel. This book provides a systematic exposition of the interplay between the two disciplines, including emerging themes pertaining to the acceleration of the development of pharmaceutical medicines to serve patients with unmet needs. Features: Regulatory and statistical interactions throughout the drug development continuum The critical role of the statistician in relation to the changing regulatory and healthcare landscapes Statistical issues that commonly arise in the course of drug development and regulatory interactions Trending topics in drug development, with emphasis on current regulatory thinking and the associated challenges and opportunities The book is designed to be accessible to readers with an intermediate knowledge of statistics, and can be a useful resource to statisticians, medical researchers, and regulatory personnel in drug development, as well as graduate students in the health sciences. The authors' decades of experience in the pharmaceutical industry and academia, and extensive regulatory experience, comes through in the many examples throughout the book.

This book provides a comprehensive overview of the concept of "Total Exposure Health" and presents details on subject areas which make up the framework. It provides in-depth coverage of the science and technology supporting exposure and risk assessment. This includes advances in toxicology and the "-omics" as well as new techniques for exposure assessment. The book concludes with a discussion on bioethics implications, including ethical considerations related to genetic testing. Discusses advances in exposure monitoring Presents a systems biology approach to human exposures Examines how overall well-being translates to worker productivity Considers the link between work-related risk factors and health conditions Covers the study of genomics in precision medicine and exposure science Explores bioethics in genomic studies Aimed at the exposure professionals (industrial hygienists, toxicologists, public health, environmental engineers), geneticists, molecular biologists, engineers and managers in the health and safety industry as well as professionals in the public administration field.

Provides an excellent grounding in the basics of both statistics and epidemiology. Full step-by-step guidance on performing statistical calculations. Numerous examples and exercises with detailed answers to help readers navigate these complex subjects with ease and confidence. Enables students and practitioners to make sense of the many research studies that underpin evidence-based practice. Fully revised and updated for this fifth edition, now with additional exercises and question and answers online for self-testing.

This textbook presents epidemiology in a practical manner, contextualized with discussions of theory and ethics, so that students and professionals from all academic backgrounds may develop a deep appreciation for how to conduct and interpret epidemiological research. Readers will develop skills to: -Search for and appraise literature critically, -Develop important research questions, -Design and implement studies to address those questions, -Perform and interpret fundamental statistical estimations and tests, -Consider the ethical implications of all stages of research, -Report findings in publications, and -Advocate for change in the public health setting. Epidemiology is and will remain a discipline in motion, and this textbook aims at reflecting this dynamism and keeping pace with its momentum. This textbook is not only a classroom tool with high utility but also an essential reference and guide for those engaging in research involving human subjects.

Towards a Digital Health Ecology : NHS Digital Adoption through the COVID-19 Looking Glass is about technology adoption in the UK's National Health Service (NHS) as told from the inflection point of a disaster. In 2020 the world lived through a disaster of epic proportions, devastating humanity around the globe. It took a microscopic virus to wreak havoc on our healthcare system and force the adoption of technology in a way that had never been seen before. This book tells the story of digital technology take-up in the NHS through the lens of that disaster. This book documents use of technology in the NHS through the lens of the first pandemic shock. Our healthcare system, paid for by general taxation and free at the point of demand, was conceived and developed in a firmly analogue world. Created in 1948, the NHS predates the invention of the World Wide Web by some forty years. This is not a book simply about technology, it is a study of the painful process of reengineering a mammoth and byzantine system that was built for a different era. The digital health sector is a microcosm of the wider healthcare system, through which grand themes of social inequality, public trust, private versus commercial interests, values and beliefs are played out. The sector is a clash of competing discourses: the civic and doing good for society; the market and wealth creation; the industrial creating more efficient and effective systems; the project expressed as innovation and experimentation; lastly the notion of vitality and leading a happier, healthy life. Each of these discourses exists in a state of flux and tension with the other. This book is offered as a critique of the role of digital technologies within healthcare. It is an examination of competing interests, approaches, and ideologies. It is a story of system complexity told through analysis and personal stories.

* A simple and systematic guide to the planning and performance of investigations concerned with health and disease and with health care * Offers researchers help in choosing a topic and to think about shaping objectives and ideas and to link these with the appropriate choice of method * Fully updated with new sections on the use of the Web and computer programmes freely available in the planning, performance or analysis of studies

This book summarizes findings from the National Health and Nutrition Survey Epidemiologic Follow-up Study (NHEFS) for persons 55 years of age and older at initial examination. This is the first prospective study of health and health-related behaviour in a representative sample of the US population.Included in the follow-up study approximately 10 years later were all 14,407 participants who were examined at baseline in 1971-1974 (National Health and Nutrition Survey I-NHANES I). This book reports on the 5,215 individuals who were 55-74 years of age at baseline and who could be traced for further examination.The prospective nature of this research permits the authors to estimate the incidence of new disease, to examine changes in health related behaviour over time, and to access the probability of subsequent disease, given the presence of risk factors at baseline. Their analyses provide new insights into disease causation and outcome in an aging population in the US.

Cancer is a dreaded disease. One in two people will be diagnosed with cancer within their lifetime. Medical Statistics for Cancer Studies shows how cancer data can be analysed in a variety of ways, covering cancer clinical trial data, epidemiological data, biological data, and genetic data. It gives some background in cancer biology and genetics, followed by detailed overviews of survival analysis, clinical trials, regression analysis, epidemiology, meta-analysis, biomarkers, and cancer informatics. It includes lots of examples using real data from the author's many years of experience working in a cancer clinical trials unit. Features: A broad and accessible overview of statistical methods in cancer research Necessary background in cancer biology and genetics Details of statistical methodology with minimal algebra Many examples using real data from cancer clinical trials Appendix giving statistics revision.

Global simultaneous development is becoming more necessary as the cost of developing medical products continues to grow. The strategy of using multiregional clinical trials (MRCTs) has become the preferred method for developing new medicines. Implementing the same protocol to include subjects from many geographical regions around the world, MRCTs can speed up the patient enrolment, thus resulting in quicker drug development and obtaining faster approval of the drug globally. After the publication of the editors' first volume on this topic, there have been new developments on MRCTs. The International Council for Harmonisation (ICH) issued ICH E17, a guideline document on MRCTs, in November 2017, laying out principles on MRCTs. Beyond E17, new methodologies have been developed as well. Simultaneous Global New Drug Development: Multi-Regional Clinical Trials after ICH E17 collects chapters providing interpretations of principles in ICH E17 and new ideas of implementing MRCTs. Authors are from different regions, and from academia and industry. In addition, in contrast to the first book, new perspectives are brought to MRCT from regulatory agencies. This book will be of particular interest to biostatisticians working in late stage clinical development of medical products. It will also be especially helpful for statisticians in regulatory agencies, and medical research institutes. This book is comprehensive across the MRCT topic spectrum, including Issues regarding ICH E17 Implementation MRCT Design and Analysis Methodologies Perspectives from authorities in regulatory agencies, as well as statisticians practicing in the medical product industry Many examples of real-life applications based on actual MRCTs.

The COVID-19 pandemic has disproportionately affected communities of color while highlighting the prevalence of structural racism in the United States. This crucial collection of essays, written by leading scholars from the fields of communications, political science, health, philosophy, and geography, explores the manifold ways in which the COVID-19 pandemic has impacted upon Black, Latinx, and Indigenous communities and the way we see race relations in the United States. The COVID-19 pandemic has exposed the significance of U.S. health inequalities, which the World Health Organization defines as "avoidable [and] unfair." It has also highlighted structural racism, specifically, institutions, practices, values, customs, and policies that differentially allocate resources and opportunities so as to increase inequity among racial groups. Navarro and Hernandez therefore argue that the COVID-19 pandemic has unleashed a race war in America that has further marginalized communities of color by limiting access to resources by different racial and ethnic minorities, particularly women within these communities. Moreover, the systemic policies of the past that upheld or failed to address the unequal social conditions affecting Blacks, Latinxs, and other minorities have now been magnified with COVID-19. The volume concludes by offering recommendations to prevent future humanitarian crises from exacerbating racial divisions and having a disproportionate impact upon ethnic minorities. This timely volume will be of great interest to those interested in the study of race and the social impacts of the COVID-19 pandemic in the United States.

This volume examines the ongoing, worldwide epidemiological transition in which acute infectious diseases are being superseded by chronic diseases as the predominant causes of morbidity and mortality; age at death has shifted from childhood to older adult ages; and life expectancy, population, and the proportion of older people are increasing. This transition constitutes a fundamental change in the human condition, and an understanding of the historical process behind it is thus of major importance. This study is the first to document the transition in a single country, drawing on records of cause-specific mortality since the eighteenth century in England, with comparative data from other Western countries. Alexander Mercer discusses possible causes of specific disease trends, reassessing the relative importance of "health interventions" and "standard of living" as determinants of increased life expectancy, and presents a new theory of how chronic diseases have developed. As specific microorganisms have been established as causal agents in chronic diseases that account for a significant proportion of "premature" deaths, the study suggests that a new conceptualization of the epidemiological transition is required, one that takes into account interrelationships between infectious diseases, between infections and chronic diseases, and between disorders underlying different chronic diseases. Alexander Mercer is an independent researcher and the author of Disease, Mortality and Population in Transition: Epidemiological-Demographic Change in England Since the Eighteenth Century as Part of a Global Phenomenon.

The concepts of estimands, analyses (estimators), and sensitivity are interrelated. Therefore, great need exists for an integrated approach to these topics. This book acts as a practical guide to developing and implementing statistical analysis plans by explaining fundamental concepts using accessible language, providing technical details, real-world examples, and SAS and R code to implement analyses. The updated ICH guideline raises new analytic and cross-functional challenges for statisticians. Gaps between different communities have come to surface, such as between causal inference and clinical trialists, as well as among clinicians, statisticians, and regulators when it comes to communicating decision-making objectives, assumptions, and interpretations of evidence. This book lays out a path toward bridging some of these gaps. It offers ? A common language and unifying framework along with the technical details and practical guidance to help statisticians meet the challenges ? A thorough treatment of intercurrent events (ICEs), i.e., postrandomization events that confound interpretation of outcomes and five strategies for ICEs in ICH E9 (R1) ? Details on how estimands, integrated into a principled study development process, lay a foundation for coherent specification of trial design, conduct, and analysis needed to overcome the issues caused by ICEs: ? A perspective on the role of the intention-to-treat principle ? Examples and case studies from various areas ? Example code in SAS and R ? A connection with causal inference ? Implications and methods for analysis of longitudinal trials with missing data Together, the authors have offered the readers their ample expertise in clinical trial design and analysis, from an industrial and academic perspective.

This book looks at the institutional and governance issues faced by India during the first and second wave of the COVID-19 pandemic and its adverse impact on the vulnerable sectors and groups. The book is split into four parts, with preceding chapters informing later ones. Part One outlines the approach of the study, in particular their examination of policy responses and the effect of the pandemic. Part Two delves into the governance challenges in containing the pandemic while giving the theoretical rationale for institutional responses. Part Three looks at how the pandemic affected economically vulnerable households, workers, and small industries. The effect of pandemic on the informal sector is also detailed. Lastly, Part Four examines the impacts and responses of Indian public infrastructure and services to the pandemic, in particular the impact of the COVID-19 pandemic on health care and schooling. It also explores the challenges caused by infrastructure inadequacies in Indian cities. The book closes by looking at how businesses in the private sector have responded to the COVID-19 pandemic, with a focus on Corporate Social Responsibility. The book will be a useful reference to researchers, policymakers, and practitioners who are interested in institutions and development, especially in the context of India.